Transaction DateRecipientSharesTypePriceValue
16th September 2020Capital, Llc Armistice100Open or private purchase$3.75$375.00
16th September 2020Capital, Llc Armistice0Open or private sale$0.00
16th September 2020Capital, Llc Armistice125,000Open or private sale$0.16$20,000.00
16th September 2020Capital, Llc Armistice0Open or private purchase$0.00
15th September 2020Capital, Llc Armistice0Open or private sale$0.00
15th September 2020Capital, Llc Armistice82,084Open or private sale$0.16$13,133.44
14th September 2020Capital, Llc Armistice0Open or private sale$0.00
14th September 2020Capital, Llc Armistice130,000Open or private sale$0.17$22,100.00
11th September 2020Capital, Llc Armistice0Open or private sale$0.00
11th September 2020Capital, Llc Armistice170,000Open or private sale$0.17$28,900.00
Amag Pharmaceuticals
Amag Pharmaceuticals logo

AMAG Pharmaceuticals, Inc. focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.

Ticker: AMAG
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 792977
Employees: 440
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $54 M (-51%)
Inventory, Net: $34 M (0%)
Assets, Current: $291 M (-8%)
Property, Plant and Equipment, Net: $3 M (0%)
Assets: $754 M (-4%)
Accounts Payable, Current: $17 M (-38%)
Accrued Liabilities, Current: $168 M (0%)
Liabilities, Current: $188 M (-9%)
Long-term Debt, Excluding Current Maturities: $281 M (1%)
Other Liabilities, Noncurrent: $1 M (1158%)
Liabilities: $490 M (-3%)
Common Stock, Value, Issued: $342 Th (0%)
Common Stock, Shares, Issued: $34 M (0%)
Additional Paid in Capital, Common Stock: $1 B (0%)
Retained Earnings (Accumulated Deficit): $1 B (2%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $4 M (16%)
Stockholders' Equity (Parent): $264 M (0%)
Liabilities and Equity: $754 M (-4%)
Revenue: $69 M (-9%)
Cost of Revenue: $24 M (31%)
Restructuring Charges: $0 (-100%)
Operating Income/Loss: $20 M (-83%)
Other Income, net: $5 M (6%)
Provision for income taxes: $100 Th (0%)